Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International Immunology

• Publication date

  2018-04-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/intimm/dxy006PMID 29617862
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity

  2019cited by this paper
• Sharpening the Molecular Scissors: Advances in Gene-Editing Technology

  2019cited by this paper
• Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

  2016cited by this paper
• Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.

  2016cited by this paper
• Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

  2016cited by this paper
• Generation of knock-in primary human T cells using Cas9 ribonucleoproteins

  2015cited by this paper
• Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection.

  2015cited by this paper
• Development and applications of CRISPR-Cas9 for genome engineering.

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• Crystal structure of Cas9 in complex with guide RNA and target DNA.

  2014cited by this paper
• FFAS-3D: improving fold recognition by including optimized structural features and template re-ranking

  2014cited by this paper
• Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.

  2014cited by this paper
• Adoptive T-cell therapy: adverse events and safety switches

  2014cited by this paper
• The new frontier of genome engineering with CRISPR-Cas9

  2014cited by this paper
• CRISPR-Cas systems for editing, regulating and targeting genomes

  2014cited by this paper
• Reassessing target antigens for adoptive T cell therapy

  2013cited by this paper
• Gene-engineered T cells for cancer therapy

  2013cited by this paper
• How good is automated protein docking?

  2013cited by this paper
• Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.

  2012cited by this paper
• T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

  2011cited by this paper
• Affinity Thresholds for Naive CD8+ CTL Activation by Peptides and Engineered Influenza A Viruses

  2011cited by this paper
• T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis.

  2011cited by this paper
• Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

  2010cited by this paper
• Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

  2010cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100.

  2009cited by this paper
• Supplemental Data Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins

  2009cited by this paper
• Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins.

  2009cited by this paper
• Improved prediction of protein side‐chain conformations with SCWRL4

  2009cited by this paper
• Comparative Protein Structure Modeling Using MODELLER

  2007cited by this paper
• Human TCR-Binding Affinity is Governed by MHC Class Restriction1

  2007cited by this paper
• Comparative Protein Structure Modeling Using Modeller

  2006cited by this paper
• High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.

  2006cited by this paper
• MUSCLE: multiple sequence alignment with high accuracy and high throughput.

  2004cited by this paper
• ClusPro: an automated docking and discrimination method for the prediction of protein complexes

  2004cited by this paper
• A Single Heteroclitic Epitope Determines Cancer Immunity After Xenogeneic DNA Immunization Against a Tumor Differentiation Antigen1

  2003cited by this paper
• Plat-E: an efficient and stable system for transient packaging of retroviruses

  2000cited by this paper
• B16 as a Mouse Model for Human Melanoma

  2000cited by this paper
• Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen.

  1998cited by this paper
• gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

  1998cited by this paper
• proteins STRUCTURE O FUNCTION O BIOINFORMATICS Improved prediction of protein side-chain conformations with SCWRL4

  year unknowncited by this paper

• Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

  2025cites this paper
• Single-cell analysis of temporal immune cell dynamics in alopecia areata reveals a causal role for clonally expanded CD8+ T cells in disease.

  2025cites this paper
• Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes

  2024cites this paper
• Synergistic antitumor effect of shRNA knock-down PD-1 combined with CD30-CAR-T

  2022cites this paper
• ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.

  2021cites this paper
• Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.

  2021cites this paper
• PD-1 suppresses the osteogenic and odontogenic differentiation of stem cells from dental apical papilla via targeting SHP2/NF-κB axis.

  2021cites this paper
• Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease

  2020cites this paper
• Improving Cancer Immunotherapy with CRISPR‐Based Technology

  2020cites this paper
• Generation of mouse model of TGFBI-R124C corneal dystrophy using CRISPR/Cas9-mediated homology-directed repair

  2020cites this paper
• Sharpening the Molecular Scissors: Advances in Gene-Editing Technology

  2019cites this paper
• PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity

  2019cites this paper